The Diagnostic and Prognostic Utility of Contemporary Cardiac Magnetic Resonance in Suspected Acute Myocarditis
- PMID: 35054323
- PMCID: PMC8774755
- DOI: 10.3390/diagnostics12010156
The Diagnostic and Prognostic Utility of Contemporary Cardiac Magnetic Resonance in Suspected Acute Myocarditis
Abstract
Cardiovascular magnetic resonance (CMR) is used to investigate suspected acute myocarditis, however most supporting data is retrospective and few studies have included parametric mapping. We aimed to investigate the utility of contemporary multiparametric CMR in a large prospective cohort of patients with suspected acute myocarditis, the impact of real-world variations in practice, the relationship between clinical characteristics and CMR findings and factors predicting outcome. 540 consecutive patients we recruited. The 113 patients diagnosed with myocarditis on CMR performed within 40 days of presentation were followed-up for 674 (504-915) days. 39 patients underwent follow-up CMR at 189 (166-209) days. CMR provided a positive diagnosis in 72% of patients, including myocarditis (40%) and myocardial infarction (11%). In multivariable analysis, male sex and shorter presentation-to-scan interval were associated with a diagnosis of myocarditis. Presentation with heart failure (HF) was associated with lower left ventricular ejection fraction (LVEF), higher LGE burden and higher extracellular volume fraction. Lower baseline LVEF predicted follow-up LV dysfunction. Multiparametric CMR has a high diagnostic yield in suspected acute myocarditis. CMR should be performed early and include parametric mapping. Patients presenting with HF and reduced LVEF require closer follow-up while those with normal CMR may not require it.
Keywords: magnetic resonance imaging; myocarditis; parametric mapping.
Conflict of interest statement
Miller received research support from Amicus Therapeutics, Guerbet Laboratories Limited, Roche and Univar Solutions B.V. outside of the submitted work. Miller also served on an advisory board for Novartis, Boehringer Ingelheim and Lilly Alliance and AstraZeneca and serves as an advisor for HAYA therapeutics and PureTech Health. The other authors for this manuscript do not have any conflicts of interest to declare.
Figures


References
-
- Luetkens J.A., Homsi R., Dabir D., Kuetting D.L., Marx C., Doerner J., Schlesinger-Irsch U., Andrié R., Sprinkart A.M., Schmeel F.C., et al. Comprehensive Cardiac Magnetic Resonance for Short-Term Follow-Up in Acute Myocarditis. J. Am. Heart Assoc. 2016;5 doi: 10.1161/JAHA.116.003603. - DOI - PMC - PubMed
-
- Bohnen S., Radunski U., Lund G., Ojeda F., Looft Y., Senel M., Radziwolek L., Avanesov M., Tahir E., Stehning C., et al. Tissue characterization by T1 and T2 mapping cardiovascular magnetic resonance imaging to monitor myocardial inflammation in healing myocarditis. Eur. Heart J.-Cardiovasc. Imaging. 2017;18:744–751. doi: 10.1093/ehjci/jex007. - DOI - PubMed
-
- Baeßler B., Schaarschmidt F., Dick A., Stehning C., Schnackenburg B., Michels G., Maintz D., Bunck A.C. Mapping tissue inhomogeneity in acute myocarditis: A novel analytical approach to quantitative myocardial edema imaging by T2-mapping. J. Cardiovasc. Magn. Reson. 2015;17:115. doi: 10.1186/s12968-015-0217-y. - DOI - PMC - PubMed
-
- Bohnen S., Radunski U.K., Lund G.K., Kandolf R., Stehning C., Schnackenburg B., Adam G., Blankenberg S., Muellerleile K. Performance of T1 and T2 Mapping Cardiovascular Magnetic Resonance to Detect Active Myocarditis in Patients with Recent-Onset Heart Failure. Circ. Cardiovasc. Imaging. 2015;8:e003073. doi: 10.1161/CIRCIMAGING.114.003073. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous